Skip to search formSkip to main contentSkip to account menu

Montanide ISA-51/peptide 946-tetanus peptide conjugate melanoma vaccine

Known as: ISA-51/p946-Tet p, ISA-51/p946/Tet p, Montanide ISA-51/peptide 946 melanoma vaccine/tetanus peptide melanoma vaccine 
National Institutes of Health

Related topics

Related topics

3 relations
incomplete Freund's adjuvantpeptide 946 melanoma vaccinetetanus peptide melanoma vaccine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer.
Highly Cited
2011
Highly Cited
2011
The Requirement for Potent Adjuvants To Enhance the Immunogenicity and Protective Efficacy of Protein Vaccines Can Be Overcome by Prior Immunization with a Recombinant Adenovirus
A central goal in vaccinology is the induction of high and sustained Ab responses. Protein-in-adjuvant formulations are commonly… 
2006
2006
Vigorous hepatitis C virus-specific CD4+ and CD8+ T cell responses induced by protein immunization in the presence of Montanide ISA720 plus synthetic oligodeoxynucleotides containing…
BACKGROUND A prophylactic vaccine for hepatitis C virus (HCV) requires generation of strong humoral as well as CD4(+) and CD8… 
2004
2004
Full Protection in Pigs against FMDV Challenge following Single Dose of Synthetic Emergency FMD Vaccine
Introduction: The UBITh ® -VP1 synthetic peptide-based vaccine for FMDV O, formulated as a water-in-oil emulsion, was evaluated… 
1999
1999
The V3 loop based multi-epitope polypeptide TAB9 adjuvated with montanide ISA720 is highly immunogenic in nonhuman primates and induces neutralizing antibodies against five HIV-1 isolates.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)